Loading bill breakdown…
H.R. 1262119th CongressHealth
Mikaela Naylon Give Kids a Chance Act
Sponsored by Rep. Michael T. McCaul (R-TX) · 313 active : 132 Republicans, 180 Democrats, 1 Independent
Latest action: Received in the Senate.
Where it standsPassed House, now in the Senate7 senators score as swing votes
Passed House
- House: passedDec 1, 2025
- Senate: next
- President: not yet
Summary
, via Congress.govGive Kids a Chance Act of 2025
This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.
Specifically, the bill
modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;
Read full summaryHide full summary
permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;
renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and
reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.
The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In
Catalyst Pharmaceuticals, Inc. v. Becerra
, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
Committees and subjects
Committees
- House Committee on Energy and Commerce · HouseReported by · Markup by · Referred to
Subjects
- Arab-Israeli relations
- Bahrain
- Cancer
- Child health
- Computers and information technology
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Food and Drug Administration (FDA)
- Government information and archives
- Government studies and investigations
- Health information and medical records
Show all 23 subjects
- International law and treaties
Model
Directional: count only breaks toward the other partyWhy do scores change?v3default (selected)v2 model swing-v2
How the Senate breaks down
- 7Swing 70–100
- 66Middle 30–70
- 27Entrenched 0–30
Members fall into . All 100 senators have enough data to score.
Key players in the Senate
Ranked by swing score, 0–100 · swing-v3Bars show each input from 0 to 100: ideology gap, scorecard gap, , and the . is the seat’s partisan lean, and shows how much of the input data a score has.
Similar past votes, Senate
Earlier behind swing-v3’s inputLoading similar votes
Cosponsors
313 activeShow all 313 cosponsors
- Dan Crenshaw (R-TX-2)
- Debbie Dingell (D-MI-6)
- Diana Harshbarger (R-TN-1)
- Doris O. Matsui (D-CA-7)
- Gus M. Bilirakis (R-FL-12)
- Kathy Castor (D-FL-14)
- Kim Schrier (D-WA-8)
- Lori Trahan (D-MA-3)
- Mike Kelly (R-PA-16)
- Randy K. Sr. Weber (R-TX-14)
- Ben Cline (R-VA-6)
- Carlos A. Gimenez (R-FL-28)
- Carol D. Miller (R-WV-1)
- Clay Higgins (R-LA-3)
- Darren Soto (D-FL-9)
- Debbie Wasserman Schultz (D-FL-25)
- Ed Case (D-HI-1)
- Eleanor Holmes Norton (D-DC-AL)
- Gabe Evans (R-CO-8)
- Joaquin Castro (D-TX-20)
- Kevin Mullin (D-CA-15)
- LaMonica McIver
How the swing score works
Ideology gapHow far a member’s DW-NOMINATE voting score sits from their party’s median in the same chamber.
Scorecard gapHow far their Heritage Action and LCV ratings stray from their party’s average, using the groups’ votes on similar bills where available.
Cross-pressureHow strongly their district or state leans toward the other party, from our own computed partisan lean.
Similar votesHow often they voted against their own party on earlier roll calls about this bill or similar ones.
Committee bonusMembers of the committees handling the bill decide whether it moves, so they get a boost.
Cosponsor checkThe sponsor and active cosponsors have already committed, so they drop toward entrenched.
